autologous iNSC-DAP
/ Huixin Medical Valley
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 13, 2023
Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease
(clinicaltrials.gov)
- P1 | N=10 | Recruiting | Sponsor: Xuanwu Hospital, Beijing
New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease
1 to 1
Of
1
Go to page
1